Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 8, 2007, Pages 557-561

  Choi, S H ^a,b   Lee, J E ^a,b   Park, S J ^a,b   Kim, M N ^a,b   Choo, E J ^a,b,c   Kwak, Y G ^a,b,d   Jeong, J Y ^a,b   Woo, J H ^a,b   Kim, N J ^a,b   Kim, Y S ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Inje University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ACUTE HEMORRHAGIC PANCREATITIS; ADULT; AGED; ARTICLE; CHOLANGITIS; CITROBACTER FREUNDII; CONTROLLED STUDY; DIABETIC FOOT; ENTEROBACTER; HUMAN; INFECTION; KOREA; MALE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; SERRATIA MARCESCENS; URINARY TRACT INFECTION;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; KOREA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; ROC CURVE;

EID: 34547136169     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0308-2     Document Type: Article

References (12)

1. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585-590
2. Ho PL, Shek RH, Chow KH, Duan RS, Mak GC, Lai EL, Yam WC, Tsang KW, Lai WM (2005) Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J Antimicrob Chemother 55:326-332
3. Kim J, Lim YM (2005) Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 43:2452-2455
4. Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ (2004) High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 48:3159-3161
5. Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ, Lee K (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265-269
6. Clinical and Laboratory Standards Institute (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6: 6th edition. CLSI, Villanova, PA
7. Jacoby GA, Han P (1996) Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 34:908-911
8. Sanders CC, Sanders WE Jr, Goering RV (1982) In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother 21:968-975
9. Sanders CC, Sanders WE Jr (1979) Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother 15:792-797
10. Schwaber MJ, Raney PM, Rasheed JK, Biddle JW, Williams P, McGowan JE Jr, Tenover FC (2004) Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobactericeae. J Clin Micriobiol 42:294-298
11. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A; Cefepime Study Group (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442-3447
12. Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, Van Herck K, Jorens PG, Demey HE, Ieven M, Bossaert L, Goossens H (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12:56-62